Literature DB >> 19743453

Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy.

Marcel M Verbeek1, Berry P H Kremer, Marcel Olde Rikkert, Peter H M F Van Domburg, Maureen E Skehan, Steven M Greenberg.   

Abstract

Cerebral amyloid angiopathy is caused by deposition of the amyloid beta protein in the cerebral vasculature. In analogy to previous observations in Alzheimer disease, we hypothesized that analysis of amyloid beta(40) and beta(42) proteins in the cerebrospinal fluid might serve as a molecular biomarker. We observed strongly decreased cerebrospinal fluid amyloid beta(40) (p < 0.01 vs controls or Alzheimer disease) and amyloid beta(42) concentrations (p < 0.001 vs controls and p < 0.05 vs Alzheimer disease) in cerebral amyloid angiopathy patients. The combination of amyloid beta(42) and total tau discriminated cerebral amyloid angiopathy from controls, with an area under the receiver operator curve of 0.98. Our data are consistent with neuropathological evidence that amyloid beta(40) as well as amyloid beta(42) protein are selectively trapped in the cerebral vasculature from interstitial fluid drainage pathways that otherwise transport amyloid beta proteins toward the cerebrospinal fluid.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19743453      PMCID: PMC3697750          DOI: 10.1002/ana.21694

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  19 in total

1.  Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria.

Authors:  K A Knudsen; J Rosand; D Karluk; S M Greenberg
Journal:  Neurology       Date:  2001-02-27       Impact factor: 9.910

2.  Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type.

Authors:  E Levy; M D Carman; I J Fernandez-Madrid; M D Power; I Lieberburg; S G van Duinen; G T Bots; W Luyendijk; B Frangione
Journal:  Science       Date:  1990-06-01       Impact factor: 47.728

3.  Cerebral amyloid angiopathy: the vascular pathology and complications.

Authors:  T I Mandybur
Journal:  J Neuropathol Exp Neurol       Date:  1986-01       Impact factor: 3.685

4.  Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

Authors:  T Iwatsubo; A Odaka; N Suzuki; H Mizusawa; N Nukina; Y Ihara
Journal:  Neuron       Date:  1994-07       Impact factor: 17.173

5.  Impaired visual evoked flow velocity response in cerebral amyloid angiopathy.

Authors:  E E Smith; M Vijayappa; F Lima; P Delgado; L Wendell; J Rosand; S M Greenberg
Journal:  Neurology       Date:  2008-10-28       Impact factor: 9.910

Review 6.  Amyloid angiopathy-related vascular cognitive impairment.

Authors:  Steven M Greenberg; M Edip Gurol; Jonathan Rosand; Eric E Smith
Journal:  Stroke       Date:  2004-09-30       Impact factor: 7.914

7.  Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease.

Authors:  D L Miller; I A Papayannopoulos; J Styles; S A Bobin; Y Y Lin; K Biemann; K Iqbal
Journal:  Arch Biochem Biophys       Date:  1993-02-15       Impact factor: 4.013

8.  Hereditary cerebral hemorrhage with amyloidosis (Dutch): a model for congophilic plaque formation without neurofibrillary pathology.

Authors:  M L Maat-Schieman; C M Radder; S G van Duinen; J Haan; R A Roos
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

Review 9.  Brain parenchymal and microvascular amyloid in Alzheimer's disease.

Authors:  H V Vinters; Z Z Wang; D L Secor
Journal:  Brain Pathol       Date:  1996-04       Impact factor: 6.508

10.  Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor.

Authors:  Judianne Davis; Feng Xu; Rashid Deane; Galina Romanov; Mary Lou Previti; Kelly Zeigler; Berislav V Zlokovic; William E Van Nostrand
Journal:  J Biol Chem       Date:  2004-02-25       Impact factor: 5.157

View more
  60 in total

1.  CSF biomarkers for Alzheimer's disease: current utility and potential future use.

Authors:  David M Holtzman
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations.

Authors:  Pratishtha Chatterjee; Anne M Fagan; Chengjie Xiong; Matthew McKay; Atul Bhatnagar; Yunqi Wu; Abhay K Singh; Kevin Taddei; Ian Martins; Samantha L Gardener; Mark P Molloy; Gerhard Multhaup; Colin L Masters; Peter R Schofield; Tammie L S Benzinger; John C Morris; Randall J Bateman; Steven M Greenberg; Marieke J H Wermer; Mark A van Buchem; Hamid R Sohrabi; Ralph N Martins
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

3.  Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers.

Authors:  Aaron P Schultz; Reina W Kloet; Hamid R Sohrabi; Louise van der Weerd; Sanneke van Rooden; Marieke J H Wermer; Laure Grand Moursel; Maqsood Yaqub; Bart N M van Berckel; Pratishtha Chatterjee; Samantha L Gardener; Kevin Taddei; Anne M Fagan; Tammie L Benzinger; John C Morris; Reisa Sperling; Keith Johnson; Randall J Bateman; M Edip Gurol; Mark A van Buchem; Ralph Martins; Jasmeer P Chhatwal; Steven M Greenberg
Journal:  Ann Neurol       Date:  2019-08-12       Impact factor: 10.422

4.  Cerebral microbleeds topography and cerebrospinal fluid biomarkers in cognitive impairment.

Authors:  Sara Shams; Tobias Granberg; Juha Martola; Andreas Charidimou; Xiaozhen Li; Mana Shams; Seyed-Mohammad Fereshtehnejad; Lena Cavallin; Peter Aspelin; Maria Wiberg-Kristoffersen; Lars-Olof Wahlund
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-21       Impact factor: 6.200

5.  Advances in our Understanding of the Pathophysiology, Detection and Management of Cerebral Amyloid Angiopathy.

Authors:  Octavio M Pontes-Neto; Eitan Auriel; Steven M Greenberg
Journal:  Eur Neurol Rev       Date:  2012

Review 6.  Diagnosis of Cerebral Amyloid Angiopathy: Evolution of the Boston Criteria.

Authors:  Steven M Greenberg; Andreas Charidimou
Journal:  Stroke       Date:  2018-01-15       Impact factor: 7.914

Review 7.  Biomarkers in translational research of Alzheimer's disease.

Authors:  Rawan Tarawneh; David M Holtzman
Journal:  Neuropharmacology       Date:  2010-04-13       Impact factor: 5.250

Review 8.  Cerebral amyloid angiopathy in the elderly.

Authors:  Anand Viswanathan; Steven M Greenberg
Journal:  Ann Neurol       Date:  2011-12       Impact factor: 10.422

9.  Pseudotumoral presentation of cerebral amyloid angiopathy-related inflammation.

Authors:  Solène Ronsin; Gianluca Deiana; Ana Filipa Geraldo; Françoise Durand-Dubief; Laure Thomas-Maisonneuve; Maïté Formaglio; Virginie Desestret; David Meyronet; Norbert Nighoghossian; Yves Berthezène; Jérôme Honnorat; François Ducray
Journal:  Neurology       Date:  2016-02-05       Impact factor: 9.910

10.  Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals.

Authors:  Ricardo S Osorio; Indu Ayappa; Janna Mantua; Tyler Gumb; Andrew Varga; Anne M Mooney; Omar E Burschtin; Zachary Taxin; Emmanuel During; Nicole Spector; Milton Biagioni; Elizabeth Pirraglia; Hiuyan Lau; Henrik Zetterberg; Kaj Blennow; Shou-En Lu; Lisa Mosconi; Lidia Glodzik; David M Rapoport; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2013-12-27       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.